All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer.   View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Fast & furious: looking ahead to next-generation treatments & new combinations in lymphoma?

By Stephanie Hill

Share:

Featured:

Maria PalombaMaria Palomba

Jun 5, 2019


At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, Maria Lia Palomba, Memorial Sloan Kettering Cancer Center, US discusses the future of CAR T- cells.

Dr. Lia Palomba expresses delighted at the initial results of CAR T-cell therapy for lymphoma, with the responses being durable and intriguing, however about 30 % of patients don’t respond and about 60 % will relapse eventually, so investigators are trying to modify the CAR T-cell therapy from the available results. Dr. Lia Palomba then discussed other avenues that are being explored such as more powerful CAR T-cells where the CAR constructs are being modified so that they can secrete cytokines that can preferentially expand certain types of T cells. There are also combinations that are being explored, where CAR T-cells are being combined with anti-PD1 or anti PDL1 antibodies with 3 clinical trials exploring this possibility.

Fast & furious: looking ahead to next-generation treatments & new combinations in lymphoma?

Your opinion matters

Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?